Vaginal Biome Science

What Vaginal Biome Science does

Vaginal Biome Science (VBS) is a privately held biotechnology R&D company founded in 2021 by Wendy Strgar and headquartered in Portland, Oregon, with additional R&D operations in Lambertville, New Jersey. The company develops patented BioMatch® biomimetic formulations (iso-osmolar, lactic acid-based products designed to optimize vaginal pH and support Lactobacillus dominance) alongside a proprietary qPCR vaginal microbiota panel for precise microbiome diagnostics. Its core technology platform combines quantitative PCR testing, whole genome sequencing, AI/ML predictive modeling, and a portfolio of five granted US patents plus three pending applications, with the VENUS Study generating one of the largest observational vaginal microbiome datasets in the United States across 12 gynecological conditions.

VBS operates a B2B-centric commercial model centered on licensing its patented BioMatch formulations and vaginal microbiome support platforms to consumer health brands and CPG companies, supplemented by product certification services that validate the microbiome compatibility of third-party women's health products. It is also developing a direct-to-consumer channel that will offer at-home vaginal microbiome testing, personalized coaching, and science-backed care protocols. Primary customer segments include consumer health brands, CPG companies, women's health innovators (enterprise licensing buyers), healthcare providers and research institutions (clinical collaboration through the VENUS Study), and ultimately women experiencing chronic and acute vaginal conditions such as bacterial vaginosis, yeast infections, urinary tract infections, vulvodynia, and lichen sclerosus.

The company is led by Wendy Strgar (CEO and Founder, also founder of Good Clean Love and Womankind Care), Kim Capone, PhD (Chief Science Officer, formerly lead of microbiome-focused innovations at Johnson & Johnson Consumer), and Shanya San (Senior Clinical Trials Coordinator). Strategic academic and clinical partners include Oregon Health and Science University, Yale University School of Medicine, the Center for Pelvic Medicine, Dartmouth Hitchcock Clinics, and the Institute for Vaginal Health. No external funding rounds with disclosed amounts or institutional investors are documented; the company joined the Springboard Enterprises accelerator in March 2025.

Name

Vaginal Biome Science

Legal name

Vaginal Biome Science

Website

https://vaginalbiomescience.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Vaginal Biome Science is a privately held Portland-based biotech R&D company developing patented BioMatch biomimetic formulations and proprietary qPCR diagnostics for the vaginal microbiome. It licenses its technology to consumer health brands and CPG companies, while building the VENUS Study dataset across 12 gynecological conditions.

Ownership category

akta.pro rank

Product category

Women's Health Biotechnology

NAICS

Toilet Preparation Manufacturing (325620), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Soap, Cleaning Compound, and Toilet Preparation Manufacturing (3256)

SIC

Perfumes, Cosmetics & Other Toilet Preparations (2844), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Vaginal Moisturizers & Lubricants (CRABAIAI)

akta.pro secondary industries

Biologicals Regulatory, Testing & Quality Assurance Services (AFABAEAO), Feminine Hygiene Products (Pads, Tampons, Liners) (CRADALAG)

Keywords

• Vaginal microbiome diagnostics
• Biomimetic vaginal care
• QPCR microbiota testing
• Women's health biotechnology
• Microbiome clinical research

Headquarters

HQ city

Portland

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Licensing Royalties: Licensing clinically validated, patented BioMatch formulations and vaginal microbiome support platforms to major consumer health brands, CPG companies, and women's health innovators. Partners receive access to proprietary technology backed by rigorous research and clinical trials.
2. Product Certification Services: Certification process that validates safety of women's health consumer products against rigorous VBS verification standards. Testing services for manufacturers and brands to demonstrate product integrity and compatibility with vaginal microbiome stability, leading to certification seal.
3. Diagnostics and Testing: Future plans include at-home vaginal microbiome testing through premium DTC platform, personalized vaginal health coaching, and science-backed daily care protocols.
4. Consumer Product Sales: VBS develops and commercializes patent-backed vaginal care products including vaginal hygiene systems (vulvar wash, vaginal lactic acid gel, probiotic suppository) targeting both pre- and post-menopausal women.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Vaginal Biome Science develops and licenses patented BioMatch® biomimetic formulations and a proprietary qPCR vaginal microbiota testing panel to consumer health brands, CPG companies and healthcare providers, while running the VENUS Study to build a clinical reference database across 12 gynecological conditions. It also sells Product Certification Services for manufacturers and is developing a consumer vaginal hygiene system (vulvar wash, lactic acid gel, probiotic suppository) plus a forthcoming direct-to-consumer at-home testing and coaching platform.

Product overview

Vaginal Biome Science (VBS) is an R&D and biotechnology company offering a portfolio of products and services centered on its patented BioMatch® Technology platform. The core offering includes BioMatch® formulations (clinically proven, iso-osmolar, lactic acid-based products) and a proprietary qPCR vaginal microbiota panel for precise microbiome diagnostics. VBS also conducts the VENUS Study—one of the largest vaginal microbiome research registries in the US—and offers product certification services for manufacturers. The company is developing a vaginal hygiene system (vulvar wash, lactic acid gel, probiotic suppository), biofilm disruption solutions, and upcoming DTC consumer education platform with at-home testing. Educational services include newsletters, clinician seminars, and research partnerships via the Institute for Vaginal Health.

Differentiator

Problem solved

Functional benefit

Products and services

• BioMatch® Technology Patented biomimetic technology platform licensed by VBS to consumer health brands and CPG companies; clinically proven to optimize vaginal pH in the healthy 3.8–4.5 range, support beneficial Lactobacillus dominance, and create an inhospitable environment for pathogens through iso-osmolar formulations and a proprietary lactic acid delivery system.
• qPCR Vaginal Microbiota Panel Proprietary quantitative PCR diagnostic panel offered by VBS to healthcare providers and research collaborators to deliver precise, clinically actionable insights into the vaginal microbiome, going beyond whole-genome sequencing.
• Product Certification Services Paid certification service from VBS validating that women's health consumer products meet its standards for osmolality, pH, and Lactobacillus support, eligible for the VBS certification seal.
• Vaginal Hygiene System VBS-developed consumer product line comprising a vulvar wash, vaginal lactic acid gel and probiotic suppository, designed for pre- and post-menopausal women to manage bacterial vaginosis and support optimal vaginal health by lowering vaginal pH.

Quantifiable outcome

• Statistically significant reduction in vaginal pH from 4.56 to 4.00 at Week 11 (P=0.021)
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Institute for Vaginal Health (IVH)coreStrategic or Co-development PartnerVBS is proud to support the Institute for Vaginal Health, a non-profit organization dedicated to advancement of women's sexual health. VBS provides scientifically advanced Bio-Match vaginal care samples to healthcare providers through flagship sampling program. Partnership includes Vaginal Health Insights newsletters and clinician-focused educational offerings.
• Oregon Health and Science UniversitycoreStrategic or Co-development PartnerAcademic research partner for pathology analysis and clinical research collaboration on vaginal hygiene system studies and VENUS Study. Researchers from OHSU Pathology department co-authored publications on BV management.
• Yale University School of MedicinecoreStrategic or Co-development PartnerAcademic research partner with Department of Obstetrics and Gynecology contributing to vaginal microbiome research and clinical studies.
• The Center for Pelvic MedicinecoreStrategic or Co-development PartnerClinical research partner where Dr. Susan Kellogg-Spadt serves as Director of Female Sexual Medicine, conducting patient care, research, and education in vulvovaginal and pelvic pain specialty.
• Dartmouth Hitchcock Clinics Specialty CareminorStrategic or Co-development PartnerClinical research partner with Dr. Cathy Yi contributing to vaginal microbiome studies and clinical research.
• Healthcare & Research PartnerscoreStrategic or Co-development PartnerVBS actively collaborates with researchers and healthcare providers to advance microbiome-based solutions through clinical collaboration and scientific research. Seeking additional clinical sites for VENUS Study.
• Industry & Licensing PartnerscoreOEM/ Whitelabel/ Licensing PartnerB2B licensing partnerships bringing cutting-edge vaginal microbiome technology to consumer and medical markets through patented formulations. Target partners include major consumer health brands, CPG companies, and women's health innovators.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Evvy: Evvy is a direct competitor offering DTC vaginal microbiome testing and personalized care insights, targeting the same healthcare provider and consumer segments that VBS addresses via its qPCR panel and forthcoming DTC platform.
• Juno Bio: Juno Bio provides vaginal microbiome testing and reports, directly competing with VBS's qPCR microbiota panel and future at-home testing offering for women seeking personalized vaginal health insights.
• MicroGen DX: MicroGen DX is a clinical laboratory offering qPCR-based microbiome diagnostics (including vaginal and urinary panels), overlapping with VBS's proprietary qPCR testing technology for HCPs.
• Good Clean Love: Good Clean Love is a feminine care brand founded by VBS's same founder, Wendy Strgar, producing biome-friendly vaginal lubricants and washes — closely related party with overlapping BioMatch-style product positioning.

Emerging players

• Daye: Daye is a femtech brand developing tampons, CBD-based period care, and vaginal microbiome screening — an emerging player with adjacent femtech and vaginal-health innovation overlap.
• Luum: Luum develops a precision vaginal health platform with at-home microbiome testing and personalized insights, competing with VBS's forthcoming DTC testing and personalized coaching offering.
• The Honey Pot Company: The Honey Pot offers feminine care washes, wipes, and other consumer products positioned around microbiome-friendly, plant-derived formulations — an emerging CPG peer licensing opportunities could come from or compete with.

Broad incumbents

• Church & Dwight: Church & Dwight is a broad incumbent CPG parent of Vagisil, Summer's Eve, and other femcare brands — a key potential licensing partner and a major incumbent competitor across feminine hygiene and wash categories.
• Bayer (Consumer Health): Bayer's Consumer Health division markets Canesten and other femcare antifungal/gynecological products globally — a potential licensing counterparty and broad incumbent in vaginal health treatment categories.
• bioMérieux: bioMérieux is a global in vitro diagnostics company with microbiology and molecular testing products; relevant as a broader incumbent in the clinical microbiology and molecular diagnostics space in which VBS's qPCR panel competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vaginal-biome-science
• Instagraminstagram.com/vaginalbiomescience

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaginal Biome Science